GW Pharmaceuticals PLC- (NASDAQ:GWPH) had its target price decreased by Cantor Fitzgerald from $211.00 to $193.00 in a research note published on Monday, Marketbeat Ratings reports. Cantor Fitzgerald currently has a buy rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for GW Pharmaceuticals PLC-‘s FY2019 earnings at ($6.24) EPS.

Several other brokerages have also recently issued reports on GWPH. Bank of America restated a buy rating and set a $197.00 price objective (up from $181.00) on shares of GW Pharmaceuticals PLC- in a research note on Friday, September 28th. Morgan Stanley raised their price objective on GW Pharmaceuticals PLC- from $197.00 to $240.00 and gave the stock an overweight rating in a research note on Friday, September 28th. BidaskClub raised GW Pharmaceuticals PLC- from a hold rating to a buy rating in a research report on Saturday, September 22nd. ValuEngine raised GW Pharmaceuticals PLC- from a buy rating to a strong-buy rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research raised GW Pharmaceuticals PLC- from a hold rating to a strong-buy rating and set a $168.00 target price on the stock in a research report on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $185.38.

Shares of GWPH opened at $122.72 on Monday. GW Pharmaceuticals PLC- has a 12-month low of $105.12 and a 12-month high of $179.65. The firm has a market cap of $3.83 billion, a P/E ratio of -11.62 and a beta of 2.16. The company has a current ratio of 6.66, a quick ratio of 6.34 and a debt-to-equity ratio of 0.01.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Tuesday, November 27th. The biopharmaceutical company reported ($2.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.48) by ($0.28). GW Pharmaceuticals PLC- had a negative return on equity of 50.93% and a negative net margin of 1,574.21%. The firm had revenue of $2.40 million for the quarter, compared to the consensus estimate of $2.62 million. During the same quarter last year, the business earned ($0.14) earnings per share. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. As a group, analysts predict that GW Pharmaceuticals PLC- will post -7.93 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. First Republic Investment Management Inc. increased its position in GW Pharmaceuticals PLC- by 7.4% in the second quarter. First Republic Investment Management Inc. now owns 10,031 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 688 shares during the period. LPL Financial LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 11.4% during the third quarter. LPL Financial LLC now owns 6,799 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 698 shares during the period. Van Hulzen Asset Management LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 29.3% during the second quarter. Van Hulzen Asset Management LLC now owns 3,245 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 735 shares during the period. IFP Advisors Inc increased its holdings in shares of GW Pharmaceuticals PLC- by 103.4% during the third quarter. IFP Advisors Inc now owns 1,448 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 736 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new position in shares of GW Pharmaceuticals PLC- during the second quarter valued at $109,000. 69.38% of the stock is currently owned by hedge funds and other institutional investors.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: Find a Trading Strategy That Works

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.